NTLA Shareholders Have Opportunity to Lead Intellia Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors ...
Pharmabiz1d
Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran
Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran: Cambridge, Massachusetts Saturday, April 5, 2025, 18:00 Hrs [IST] Intellia Therapeu ...
American Century Companies Inc. Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
American Century Companies Inc. increased its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 3.5% in ...
Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN
The trial is structured to assess the safety and efficacy of the therapy in approximately 50 ATTRv-PN subjects.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd.
Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by ...
7 Top Gene-Editing Stocks to Buy
Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...
NTLA Investors Have Opportunity To Lead Intellia Therapeutics Securities Fraud Lawsuit With Faruqi & Faruqi, LLP
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hund ...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...
Le Lézard3d
NTLA Deadline: NTLA Investors with Losses in Excess of $100K Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), ...
Editas Medicine: Do The Risks Outweigh The Rewards?
Editas Medicine struggles with underwhelming data and lacks major partnerships. Find out why EDIT stock faces significant ...
Intellia Therapeutics announces first patient dosed in MAGNITUDE-2 trial
Intellia Therapeutics (NTLA) announced the first patient has been dosed in MAGNITUDE-2, a global, pivotal Phase 3 trial of nexiguran ...